fulvestrant has been researched along with palbociclib in 116 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 61 (52.59) | 24.3611 |
| 2020's | 55 (47.41) | 2.80 |
| Authors | Studies |
|---|---|
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Bilban, M; Giessrigl, B; Gollinger, M; Jäger, W; Jeitler, M; Kalipciyan, M; Krieger, S; Krupitza, G; Mader, RM; Schmidt, WM | 1 |
| Alley, HM; Arndt, KT; Crowder, R; Dann, SG; Eisele, K; Ellis, MJ; Griffin, E; Lai, JP; Li, S; McDonnell, DP; Norris, JD; Primeau, T; Shao, J; VanArsdale, T; Wardell, SE | 1 |
| André, F; Cristofanilli, M; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Iwata, H; Koehler, M; Loi, S; Loibl, S; Randolph, S; Ro, J; Turner, NC; Verma, S; Zhang, K | 1 |
| Harding, E | 1 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Finkelstein, MB; Hu, W; Jessen, BA; Khan, NK; Sacaan, AI; Sung, T; Thibault, S | 1 |
| Bartlett, CH; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Im, SA; Iwata, H; Jiang, Y; Koehler, M; Loi, S; Masuda, N; Ro, J; Slamon, D; Theall, KP; Turner, NC; Verma, S; Zhang, K | 1 |
| André, F; Bartlett, CH; Bhattacharyya, H; Cristofanilli, M; Harbeck, N; Iwata, H; Iyer, S; Loi, S; Loibl, S; Puyana Theall, K; Ro, J; Turner, N; Verma, S | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, AM; Harbeck, N; Iwata, H; Loi, S; Ro, J; Rugo, HS; Schnell, P; Thiele, A; Turner, NC; Verma, S; Zhang, K | 1 |
| Amiri-Kordestani, L; Bloomquist, E; Chen, W; Fourie Zirkelbach, J; Fu, W; Kim, G; Kluetz, PG; Liu, Q; McKee, AE; Palmby, TR; Pazdur, R; Sridhara, R; Tang, S; Tilley, A; Walker, AJ; Wedam, S | 1 |
| Bonnefoi, H; Grellety, T; Iggo, R; MacGrogan, G; Richard, E; Velasco, V | 1 |
| Bao, H; Barry, E; Bihani, T; Bradford, J; Collins, M; D'Cruz, CM; Fawell, S; Goeppert, AU; Hearne, K; Hollingsworth, R; Hurt, E; Jalla, S; Ladd, B; Lai, Z; Mazzola, AM; Mohseni, M; Reimer, C; Renshaw, JG; Weir, HM; Zinda, M | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Niraula, S; Ocana, A | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Lücking, U; Sirvent, JA | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Fan, M; Hu, X; Huang, W | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Kim, ES; Scott, LJ | 1 |
| André, F; Bartlett, CH; Cristofanilli, M; Dowsett, M; Folkerd, E; Harbeck, N; Hoffman, J; Im, SA; Iwata, H; Loi, S; Loibl, S; Masuda, N; Puyana Theall, K; Ro, J; Turner, NC; Verma, S; Zhang, K | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Freedman, RA; Tolaney, SM | 1 |
| Augereau, P; Campion, L; Campone, M; Caroline, F; du Rusquec, P; Dumas, L; Frenel, JS; Gourmelon, C; Palpacuer, C; Patsouris, A; Robert, M | 1 |
| Cox, DG; Pivot, X | 1 |
| Bisagni, G; Colleoni, M; De Fato, R; Del Mastro, L; Frassoldati, A; Gianni, L; Mansutti, M; Valagussa, P; Viale, G; Zamagni, C; Zambetti, M | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC | 1 |
| Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Huang, X; Koehler, M; Liu, Y; Morden, JP; O'Leary, B; Turner, NC | 1 |
| Sidaway, P | 2 |
| Gonçalves, A | 1 |
| Abdel-Razeq, H | 1 |
| Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC | 1 |
| Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S | 1 |
| Augereau, P; Campone, M; Chassain, K; Guillemois, S; Le Corre, Y; Patsouris, A; Peyraga, G | 1 |
| Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D | 1 |
| Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Huang, X; Im, SA; Liu, Y; Loi, S; Masuda, N; Slamon, DJ; Theall, KP; Turner, NC; Verma, S | 1 |
| André, F; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Huang, X; Im, SA; Iwata, H; Loi, S; Loibl, S; Masuda, N; Puyana Theall, K; Ro, J; Slamon, DJ; Turner, NC; Verma, S | 1 |
| Jeselsohn, R; Schiff, R | 1 |
| Gibson, K; Iyer, S; Milligan, G; Mitra, D; Taylor-Stokes, G; Waller, J | 1 |
| Hara, F; Hashigaki, S; Huang, X; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Mukai, H; Muramatsu, Y; Nagasawa, T; Nakamura, R; Ohno, S; Rai, Y; Umeyama, Y | 1 |
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Cohen, O; Cuoco, MS; Freeman, S; Helvie, K; Kapstad, C; Lin, NU; Ma, CX; Marini, L; Nayar, U; Oliver, N; Painter, C; Persky, NS; Regev, A; Rozenblatt-Rosen, O; Wagle, N; Waks, AG; Wander, SA; Winer, EP | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Batra, A; Gupta, VG; Naik, RD | 1 |
| Cristofanilli, M; Huang, X; Turner, NC | 1 |
| McCaw, ZR; Vassy, JL; Wei, LJ | 1 |
| André, F; Arnedos, M; Bayar, MA; Colleoni, M; Cristofanilli, M; DeMichele, A; Giorgetti, C; Harbeck, N; Huang Bartlett, C; Liu, Y; Loi, S; Loibl, S; Michiels, S; Turner, NC; Zhang, Z; Zhu, Z | 1 |
| Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
| Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y | 1 |
| Barry, WT; Burstein, HJ; Come, SE; DeMichele, A; Guo, H; Huang Bartlett, C; Jeselsohn, R; Koehler, M; Mayer, EL; Miller, K; Mulvey, T; Overmoyer, B; Rugo, HS; Waks, AG; Winer, EP | 1 |
| Bananis, E; Castrellon, A; Cristofanilli, M; DeMichele, AM; Finn, RS; Gelmon, KA; Huang, X; Joy, AA; Lu, DR; Mori, A; Rugo, HS; Slamon, DJ; Sleckman, B; Theall, KP | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Agarwal, S; Chang, DW | 1 |
| Exinger, D; Fischbach, C; Herrscher, H; Kalish-Weindling, M; Leblanc, J; Petit, T; Pivot, X; Velten, M | 1 |
| Tamura, K | 1 |
| Benoist, C; Bidard, FC; Bièche, I; Cabel, L; Darrigues, L; El Ayachy, R; Epaillard, N; Jeannot, E; Melaabi, S; Michel, M; Noret, A; Pierga, JY; Proudhon, C; Rampanou, A; Stern, MH; Vincent-Salomon, A | 1 |
| Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Altelaar, M; Bhamra, A; Dowsett, M; Fitzpatrick, M; Gao, Q; Johnston, SR; Leal, MF; Marangoni, E; Martin, LA; Montaudon, E; Morisset, L; Nikitorowicz-Buniak, J; Pancholi, S; Ressa, A; Ribas, R; Schuster, E; Simigdala, N; Sourd, L; Thornhill, A | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J | 1 |
| Hu, CT; Long, H; Prijatelj, V; Weng, CF | 1 |
| Arrighi, A; Ballestrero, A; Becherini, P; Brandhorst, S; Caffa, I; Cea, M; Cilli, M; Clevers, H; Cortellino, S; Cremonini, AL; De Braud, F; Driehuis, E; Ferrando, L; Gradaschi, R; Longo, VD; Mantero, C; Mastracci, L; Monacelli, F; Nencioni, A; Odetti, P; Passalacqua, M; Piacente, F; Piazza, S; Provenzani, A; Salvadori, G; Spagnolo, V; Sukkar, SG; Tagliafico, A; Valdemarin, F; Vellone, VG; Vernieri, C; Wei, M; Zoppoli, G; Zucal, C | 1 |
| Alexandrou, S; Caldon, CE; Chia, KM; Coulson, R; Fernandez, KJ; Halilovic, E; Haupt, S; Haupt, Y; Lim, E; Milioli, HH; Parker, A; Portman, N; Segara, D; Swarbrick, A; Tilley, WD; Yong, A | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| André, F; Bartlett, CH; Cristofanilli, M; Cutts, RJ; Garcia-Murillas, I; Hrebien, S; Huang, X; Liu, Y; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y | 1 |
| Bach Hamba, S; Bellesoeur, A; Brain, E; Carton, M; Cottu, P; Haroun, L; Kirova, Y; Lerebours, F; Loirat, D; Porte, B | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Bernard-Tessier, A; Bidard, FC; Bièche, I; Cabel, L; Cottu, P; Darrigues, L; Dubot, C; Geiss, R; Loirat, D; Michel, M; Pierga, JY; Proudhon, C; Ricci, F; Silveira, AB; Vincent-Salomon, A | 1 |
| Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L | 1 |
| Kudo, S; Makino, T; Tanaka, T; Umetsu, R | 1 |
| Chang, YF; Fanning, SW; Green, B; Greene, GL; Greene, ME; Komm, B; Kurleto, JD; Lainé, M; Phung, L | 1 |
| Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A | 1 |
| Garre, E; Gustafsson, A; Landberg, G; Leiva, MC; Salerno, S; Ståhlberg, A | 1 |
| Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Asakawa, H; Baba, N; Nakamura, A; Park, K; Shigekawa, T | 1 |
| Barbazán-Vázquez, FJ; Galeazzi-Martínez, V; Pampín-Sánchez, R; Pelaez-Fernández, I; Reguero-Cuervo, V; Sampedro-Gimeno, T | 1 |
| Alarcón, J; Albanell, J; Antón, A; Bezares, S; Casas, M; de la Cruz-Merino, L; de la Haba-Rodríguez, J; Fernández, I; González-Cortijo, L; Margelí, M; Martínez, MT; Martínez-Jañez, N; Moreno, F; O'Connor, M; Ramos, M; Rojo, F; Sánchez-Muñoz, A; Sánchez-Rovira, P; Santaballa, A; Virizuela, JA | 1 |
| Ballestrero, A; Benelli, M; Bergqvist, M; Bernardo, A; Bliss, JM; Bonetti, A; Cameron, D; Colleoni, M; Davies, DM; De Swert, H; Duhoux, FP; Fumagalli, D; Gebhart, G; Henry, S; Hilbers, FS; Ignatiadis, M; Jerusalem, G; Kammler, R; Loi, S; MacPherson, IR; Maibach, R; Malorni, L; McCartney, A; Migliaccio, I; Neven, P; Papadimitriou, K; Piccart, M; Regan, MM; Ruepp, B; Seles, E; Thomson, A; Tyekucheva, S; Zoppoli, G | 1 |
| Alves da Costa, F; Bernardo, C; Brito, C; Cardoso Borges, F; Ferreira, AR; Furtado, C; Lourenço, A; Martins-Branco, D; Mayer-da-Silva, A; Miranda, A; Ramos, A; Ramos, C | 1 |
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Canon, JL; Clatot, F; De La Motte Rouge, T; Delaloge, S; Hardy-Bessard, AC; Lemonnier, J; Marce, M; Marques, S; Pradines, A | 1 |
| Iwata, H; Laurent, T; Muramatsu, Y; Sawaki, M; Togo, K | 1 |
| Fu, F; Guindy, M; Kano, J; Ma, J | 1 |
| Jacobson, A | 1 |
| Alba, E; Alonso-Romero, JL; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, MI; Ciruelos, EM; Corsaro, M; Csöszi, T; de la Haba-Rodríguez, J; Gil-Gil, M; Huang, X; Kahan, Z; Margelí, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Ruiz-Borrego, M; Sánchez-Rovira, P; Santaballa, A; Thallinger, C; Turner, N; Zielinski, C | 1 |
| Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| André, F; Bananis, E; Bondarenko, I; Colleoni, M; Cristofanilli, M; DeMichele, A; Harbeck, N; Huang, X; Im, SA; Iwata, H; Kim, S; Lechuga Frean, MJ; Liu, Y; Loi, S; Loibl, S; Masuda, N; O'Leary, B; Rugo, HS; Slamon, DJ; Turner, NC | 1 |
| Atkinson, C; Hart, K; Milligan, G; Mitra, D; Mycock, K; Taylor-Stokes, G; Zhan, L | 1 |
| Abrate, P; Carretta, MT; Costantini, A; Fulgenzio, C; La Malfa, A; Lasala, R; Musicco, F; Pasquantonio, M; Petragnani, N; Proli, EM; Romagnoli, A; Sansone, M; Santoleri, F; Vici, P; Vita, F; Zeuli, M | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Callens, C; Canon, JL; Chakiba, C; Clatot, F; D'Hondt, V; Dalenc, F; de la Motte Rouge, T; Delaloge, S; Derbel, O; Dubot, C; Ferrero, JM; Frenel, JS; Garnier-Tixidre, C; Grenier, J; Hardy-Bessard, AC; Ladoire, S; Lemonnier, J; Levy, C; Lortholary, A; Mouret-Reynier, MA; Pierga, JY; Pistilli, B; Plaza, JE; Pradines, A; Sabatier, R; Stefani, L; Teixeira, L; Vegas, H | 1 |
| Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P | 1 |
| Atkinson, C; Hanson, KA; Law, EH; Milligan, G; Mitra, D; Mycock, K; Preciado, S; Taylor-Stokes, G | 1 |
| Bananis, E; Diéras, V; Finn, RS; Huang, X; Im, SA; Joy, AA; Kim, S; Loi, S; Mahtani, R; Rugo, HS; Shparyk, Y; Sleckman, B; Theall, KP; Walshe, JM | 1 |
| Abdel-Aziz, N; Abdel-Razeq, H; Abulkhair, O; Al Foheidi, M; Al Ghamdi, M; Al Zahwahry, H; Alsaleh, K; Arafah, M; Ayari, J; Bahadoor, M; Bensalem, A; Bounedjar, A; Boussen, H; Bouzid, K; Dabouz, F; Errihani, H; Filali, T; Ghosn, M; Haddaoui, A; Kandil, A; Kullab, S; Larbaoui, B; Mahfouf, H; Mezlini, A; Nabholtz, JM; Oukkal, M; Rasool, H; Saadeddine, A | 1 |
| Ishiguro, H; Iwakuma, N; Iwamoto, T; Kikawa, Y; Kobayashi, K; Masuda, N; Niikura, N; Oba, M; Okuno, T; Ozaki, S; Saji, S; Tada, H; Takeshita, T; Toh, U; Tsuneizumi, M; Watanabe, K; Yamamoto, Y | 1 |
| Berg, T; Garly, R; Glavicic, V; Jensen, MB; Khan, H; Knoop, A; Kümler, I; Olsen, J; Poulsen, PB; Volmer, L | 1 |
| Cameron, C; Law, EH | 1 |
| Decker, T; Degenhardt, T; Fasching, PA; Harbeck, N; Hoffmann, O; Kates, RE; Kümmel, S; Lüftner, D; Marschner, N; Müller, V; Otremba, B; Schem, C; Schinköthe, T; Schmidt, M; Schumacher, J; Tesch, H; Thomssen, C; Uleer, C; Warm, M; Witzel, I; Wuerstlein, R; Zaiss, M | 1 |
| Arakawa, I; Hatakeyama, S; Inoue, T; Kaneko, M; Ogura, J; Sawada, H; Shida, T; Yamaguchi, H | 1 |
| Cheng, YC; Cohen, G; Guarducci, C; Jeselsohn, R; Liu, W; Ma, W; McDonald, TO; Michor, F; Nardone, A; Stein, S | 1 |
21 review(s) available for fulvestrant and palbociclib
| Article | Year |
|---|---|
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Emerging therapies for breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Clinical Trials as Topic; Drug Carriers; Estradiol; Female; Fulvestrant; Humans; Immunoconjugates; Immunotherapy; Immunotherapy, Adoptive; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyridines; Therapies, Investigational; Tubulin Modulators | 2017 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Staging; Piperazines; Purines; Pyridines; Receptor, ErbB-2 | 2019 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen | 2018 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2019 |
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen | 2020 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia | 2021 |
31 trial(s) available for fulvestrant and palbociclib
| Article | Year |
|---|---|
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2015 |
Palbociclib for hormone receptor-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Piperazines; Postmenopause; Premenopause; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2015 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas
Topics: Adult; Aged; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Piperazines; Pyridines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Patient Reported Outcome Measures; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2016 |
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Piperazines; Premenopause; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2017 |
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Infusions, Intravenous; Injections, Intramuscular; Italy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Piperazines; Prognosis; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Quality of Life; Viscera | 2018 |
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 6; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptors, Estrogen | 2018 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2019 |
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Estrogens; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Progesterone; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Steroid; Survival Analysis | 2018 |
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Piperazines; Placebos; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2019 |
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin E; Female; Fulvestrant; Gene Expression Profiling; Humans; Neoplasm Metastasis; Oncogene Proteins; Piperazines; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger | 2019 |
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Feasibility Studies; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; North America; Piperazines; Pyridines; Receptor, ErbB-2; United States | 2020 |
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Japan; Letrozole; Middle Aged; Piperazines; Postmenopause; Premenopause; Progression-Free Survival; Pyridines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptor, ErbB-2 | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2 | 2021 |
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines | 2022 |
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Male; Piperazines; Prospective Studies; Pyridines; Thymidine Kinase | 2022 |
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patien
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Circulating Tumor DNA; Female; Fulvestrant; Humans; Mutation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Female; Fulvestrant; Humans; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptor, ErbB-2 | 2022 |
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Lymphopenia; Mutation; Neutropenia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Pulmonary Embolism; Receptor, ErbB-2; Receptors, Estrogen; Venous Thromboembolism | 2023 |
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2 | 2022 |
Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2 | 2023 |
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breas
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Quality of Life; Receptor, ErbB-2 | 2023 |
64 other study(ies) available for fulvestrant and palbociclib
| Article | Year |
|---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosomal Proteins, Non-Histone; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Methyltransferases; Piperazines; Pyridines; Receptors, Estrogen; Receptors, G-Protein-Coupled; Transcription Factors; Tumor Cells, Cultured | 2013 |
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Selective Estrogen Receptor Modulators; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Palbociclib Extends Survival in Advanced Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Piperazines; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Treatment Outcome | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cell Survival; Cellular Senescence; Dogs; Drug Synergism; Estradiol; Female; Fulvestrant; Hematopoiesis; Hematopoietic Stem Cells; Humans; Male; Models, Animal; Piperazines; Protein Kinase Inhibitors; Pyridines | 2016 |
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2016 |
The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.
Topics: Animals; Antineoplastic Agents; Apocrine Glands; Breast Neoplasms; Cellular Microenvironment; Disease Models, Animal; Estradiol; Female; Fulvestrant; Heterografts; Humans; Ki-67 Antigen; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone | 2016 |
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Receptors, Estrogen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Topics: Aminopyridines; Ataxia Telangiectasia Mutated Proteins; Cyclin-Dependent Kinases; Drug Design; Estradiol; Fulvestrant; Imatinib Mesylate; Piperazines; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Sulfoxides; Vardenafil Dihydrochloride | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles | 2017 |
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Thrombocytopenia | 2018 |
A new era for treatment development in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Fulvestrant; Humans; Neoadjuvant Therapy; Piperazines; Pyridines; Trastuzumab | 2018 |
Breast cancer: Changes in clonal dynamics predict response to palbociclib.
Topics: Breast Neoplasms; Circulating Tumor DNA; Fulvestrant; Humans; Piperazines; Pyridines | 2018 |
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases | 2018 |
Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fulvestrant; Gastroenteritis; Humans; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Patient Satisfaction; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Surveys and Questionnaires; Treatment Outcome | 2019 |
Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine.
Topics: Breast Neoplasms; Circulating Tumor DNA; Clonal Evolution; Drug Resistance; Fulvestrant; Humans; Mutation; Piperazines; Precision Medicine; Pyridines | 2018 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Piperazines; Practice Patterns, Physicians'; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2019 |
Survival data from PALOMA-3 reported.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2018 |
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |
Acquired HER2 mutations in ER
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; HEK293 Cells; Humans; MCF-7 Cells; Mutation; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2019 |
Palbociclib and Fulvestrant in Breast Cancer.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Palbociclib and Fulvestrant in Breast Cancer. Reply.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Palbociclib and Fulvestrant in Breast Cancer.
Topics: Breast Neoplasms; Fulvestrant; Humans; Piperazines; Pyridines | 2019 |
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Pyridines; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Breast reconstruction in the patient with stable, metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Life Expectancy; Mammaplasty; Mastectomy; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Quality of Life | 2020 |
Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Fulvestrant; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
A single droplet digital PCR for ESR1 activating mutations detection in plasma.
Topics: Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Exons; Female; Fulvestrant; Gene Frequency; Humans; Mutation; Piperazines; Plasma; Polymerase Chain Reaction; Prospective Studies; Pyridines | 2020 |
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Retinoblastoma Protein; RNA Interference; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Administration Schedule; Estrogens; Fatigue; Febrile Neutropenia; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Mucositis; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Thrombocytopenia | 2020 |
Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antrodia; Bone Neoplasms; Breast Neoplasms; Female; Fulvestrant; Humans; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2020 |
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
Topics: Animals; Biological Factors; Breast Neoplasms; Diet Therapy; Diet, Healthy; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Fasting; Female; Fulvestrant; Humans; Insulin; Insulin-Like Growth Factor I; Leptin; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Piperazines; PTEN Phosphohydrolase; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Humans; Isoquinolines; Mice; Mice, Inbred NOD; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyridines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2020 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase III as Topic; Female; Fulvestrant; Gene Dosage; Humans; Multicenter Studies as Topic; Mutation; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2021 |
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Proportional Hazards Models; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Young Adult | 2020 |
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Female; Fulvestrant; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2021 |
[A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines | 2021 |
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Receptor alpha; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Neoplasm Metastasis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2021 |
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines | 2021 |
Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Endocrine Cells; Female; Fulvestrant; Gene Expression; Humans; Male; MCF-7 Cells; Middle Aged; Piperazines; Pluripotent Stem Cells; Pyridines; Up-Regulation | 2021 |
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes | 2021 |
[Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyridines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen | 2021 |
Observational real world data with palbociclib associated to hormone therapy for advanced breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2021 |
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fulvestrant; Humans; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Piperazines; Pyridines; Receptor, ErbB-2 | 2022 |
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies | 2022 |
Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines; Receptors, Estrogen | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2- advanced/metastatic breast cancer in Japan: Results from the IRIS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Retrospective Studies | 2022 |
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Tapering; Duration of Therapy; Female; Fulvestrant; Humans; Retrospective Studies | 2023 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Randomized Controlled Trials as Topic; Retrospective Studies | 2022 |
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Japan; Receptor, ErbB-2; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2023 |
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denmark; Female; Fulvestrant; Humans; Receptor, ErbB-2; Retrospective Studies | 2023 |
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2 | 2023 |
Cost-Effectiveness Analysis of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib for Inoperable or Recurrent Breast Cancer.
Topics: Breast Neoplasms; Cost-Effectiveness Analysis; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans | 2023 |
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer.
Topics: Bayes Theorem; Breast Neoplasms; Female; Fulvestrant; Humans; Receptors, Estrogen | 2023 |